United States · Federal contract register · Supplier record

ASTRAZENECA PHARMACEUTICALS LP

Line: In vitro diagnostic substances, reagents, test kits and sets (6550)Register loaded to September 2026Compiled 17 October 2026

ASTRAZENECA PHARMACEUTICALS LP — United States · Federal contract register · Supplier record: 25 contracts, all years ($1,233,940,541 · Oct 2007 – Nov 2025); $1.0K since January 2024 (2 contracts · 1 agency); — rank in the line (of 334 suppliers · 0.0%); 8 agencies never served ($12.5M on the line without ASTRAZENECA PHARMACEUTICALS LP).

Assay record ASY-US-1A3O6NJ0VE · Cite as: Assay Systems, “ASTRAZENECA PHARMACEUTICALS LP: 2 government contracts in the United States since 2024”, https://assay-systems.com/register/us/astrazeneca-pharmaceuticals-lp/

25
contracts, all years
$1,233,940,541 · Oct 2007 – Nov 2025
$1.0K
since January 2024
2 contracts · 1 agency
—
rank in the line
of 334 suppliers · 0.0%
8
agencies never served
$12.5M on the line without ASTRAZENECA PHARMACEUTICALS LP

Own record by year

2019 onward
$6.5K
$1.2B
$37.0K
$29.8K
$500
$500
$500
20192020202120222023202420252026

Who buys from ASTRAZENECA PHARMACEUTICALS LP

since January 2024
1agencies
$1.0Kpaid
100.0%top buyer
Department of Defense100.0%
$1,000

Before 2024 only: Department of Health and Human Services, Department of Veterans Affairs.

Won without a rival

2024-03-30 – 2025-04-07
2uncontested awards
40%of its awards
2without a competition
0single bid

ASTRAZENECA PHARMACEUTICALS LP won 2 of its 5 public contract awards in United States without a rival from 2024-03-30 to 2025-04-07, worth $-20,322: 2 without a competition and 0 after a competition that drew a single bid. 2 buyers awarded it without a rival, the largest Centers for Disease Control and Prevention with 1.

Buyers: Centers for Disease Control and Prevention (1) · Indian Health Service (1)

Every uncontested award of ASTRAZENECA PHARMACEUTICALS LP · United States: all uncontested awards

The line

since January 2024
$534Mline value
7,757contracts
11agencies
334suppliers
61.1%held by top ten

In vitro diagnostic substances, reagents, test kits and sets (6550)

$229M
$202M
$103M
202420252026Jan–Sep
—of 334 suppliers
$0ASTRAZENECA PHARMACEUTICALS LP in the line
0.0%share of the line

Agencies that buy the line and never bought from ASTRAZENECA PHARMACEUTICALS LP

8agencies
116contracts
$12,541,228since January 2024
Department of Agriculture64 contracts
$9,629,585
Department of State21 contracts
$1,650,716
Social Security Administration2 contracts
$574,150
Environmental Protection Agency5 contracts
$327,283
Department of Justice17 contracts
$204,596
Department of the Interior5 contracts
$138,850
Department of Commerce1 contract
$15,095
General Services Administration1 contract
$952

How the line is bought

by value, since 2024
41%no competition
20%one applicant
0of these to ASTRAZENECA PHARMACEUTICALS LP
Awarded directly, no competition1,332 contracts
$221,484,668 · 41.4%
Competed, several suppliers applied5,020 contracts
$208,113,854 · 38.9%
Competed, one supplier applied1,405 contracts
$104,743,271 · 19.6%

Contracts reaching their end dates

Oct 2026 – October 2027
538contracts
$121,807,157end by October 2027
102end in September 2027 · $25.8M
10in agencies never served · $1.2M
$7.9M
$3.5M
$11.2M
$9.0M
$5.4M
$10.3M
$10.8M
$11.4M
$10.2M
$4.6M
$11.8M
$25.8M
Oct 2629 contractsNov 2623 contractsDec 2653 contractsJan 2736 contractsFeb 2737 contractsMar 2758 contractsApr 2740 contractsMay 2739 contractsJun 2745 contractsJul 2722 contractsAug 2754 contractsSep 27102 contracts

Fastest-growing supplier in the line

same line
+135%growth

Supplier UEI PU6HHX2R11C7

2024 to Sep 2026
$42,184,140
2022–2023
$17,936,792

The extract

Every buying office, every contract holder, value, number and end date behind the figures above.

Request extractSee a sample extract

Source: USAspending.gov, U.S. Department of the Treasury, Bureau of the Fiscal Service, usaspending.gov, accessed 30 September 2026.The data is available to copy, adapt, redistribute, or otherwise use for non-commercial or for commercial purposes (USAspending.gov, Licensing); no Dun & Bradstreet data is shown.